 |
14 Diseases |  |
33 Trials |
|
33 Trials |  |
2608 News |  |
| «12...1213141516171819202122...3132» |
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Disease-modifying therapy effect on COVID-19 vaccine response in multiple sclerosis patients: data from two New York State Multiple Sclerosis Consortium centers (Stream 7 Therapy / Global views) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1535;
MS patients treated with B-cell depleting medications and S1P modulators have significantly lower seroconversion after COVID-19 vaccination when compared to DMT-naïve patients and other DMT groups. Future studies should determine the risk of severe clinical outcomes in vaccinated patients with no evidence of seroconversion.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] COVID-19 vaccination and humoral immune response in people with multiple sclerosis (Stream 5 Therapy / Global views) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1507;
Some patients treated with anti-CD20 and fingolimod failed to develop a post-vaccination humoral response. Adverse events were similar to the general population.
- teriflunomide / Generic mfg.
[VIRTUAL] The effect of different national treatment strategies on disability outcome in relapsing-remitting multiple sclerosis: a propensity score adjusted comparison between Denmark and Sweden (Stream 5 Therapy / Global views) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1505;
We show for the first time that differences in treatment strategies of RRMS have an impact on disability outcomes at a national level. Escalation of treatment efficacy seemed inferior to using more efficacious DMT as initial treatment.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Comparing humoral immune response to SARS-CoV2 vaccines in multiple sclerosis and healthy controls: an Austrian multi-center study (Stream 1 Clinical) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1472;
Humoral response to SARS-CoV2 vaccines in MS patients is generally excellent. While reduced by immunosuppressive DMT, most importantly by B-cell depleting CD20mAb, protective humoral response is still expected in the majority of patients.
- | teriflunomide / Generic mfg.
Retrospective data, Journal: Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials. (Pubmed Central) - Sep 22, 2021
Serious infections occurred in 3.7%, 4.3%, and 7.1%, respectively. Long-term risk of lymphopenia and infections in patients who continue to receive teriflunomide is low, demonstrating a limited impact on adaptive and innate immunity.
- || Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Clinical, Review, Journal: Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review. (Pubmed Central) - Sep 22, 2021
Papers evaluating the following drugs were reviewed: rituximab, ocrelizumab, alemtuzumab, fingolimod, natalizumab, dimethyl fumarate, interferon, glatiramer acetate, cladribine, teriflunomide.Expert opinion: Overall, the occurrence of invasive fungal infections was low, with most infective events reported among patients treated with monoclonal antibodies and fingolimod...Although not common, these infections may be difficult to diagnose and their fatality rate is often high. For this reason, screening protocols for fungal infections must be implemented in the clinical practice when managing patients with MS.
- | teriflunomide / Generic mfg.
Journal: Teriflunomide, a potential novel cause of chronic active colitis. (Pubmed Central) - Sep 16, 2021
It is indicated as a first-line treatment for relapsing-remitting multiple sclerosis (RRMS). The most common adverse reactions reported in patients receiving either 7 or 14 mg daily include headache (18% and 16%), elevated alanine aminotransferase (13% and 15%), diarrhea (13% and 14%), alopecia (10% and 13%), and nausea (8% and 11%), respectively [2].
- | dimethyl fumarate / Generic mfg.
Journal, HEOR: Economic impact of the new oral treatments for multiple sclerosis. (Pubmed Central) - Sep 10, 2021
The most common adverse reactions reported in patients receiving either 7 or 14 mg daily include headache (18% and 16%), elevated alanine aminotransferase (13% and 15%), diarrhea (13% and 14%), alopecia (10% and 13%), and nausea (8% and 11%), respectively [2]. In addition to contributing new therapeutic alternatives, dimethyl fumarate and teriflunomide produced an economic saving in MS treatment at our hospital.
- || glatiramer acetate / Generic mfg.
Clinical, Journal: Evaluation of diagnosis and treatment practices of Brazilian neurologists among patients with multiple sclerosis. (Pubmed Central) - Sep 9, 2021
In addition to contributing new therapeutic alternatives, dimethyl fumarate and teriflunomide produced an economic saving in MS treatment at our hospital. This study enabled identification of areas of agreement and disagreement about MS treatment among Brazilian neurologists, which can be used to update future protocols and improve patient management.
- leflunomide / Generic mfg.
Leflunomide Induced Lymphocytic Gastritis (Shoreline Exhibit Hall) - Sep 8, 2021 - Abstract #ACG2021ACG_927;
Leflunomide associated lymphocytic colitis has been reported. We describe an adverse reaction of leflunomide, LG presenting as episodic bleeding gastric ulcers which resolved after discontinuation of the medication, which was hitherto not described.Figure: Gastric antrum biopsy showing prominent lymphocytes suggestive of lymphocytic gastritis
- || Ivlizi (divozilimab) / Biocad
Trial completion date: Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis (clinicaltrials.gov) - Sep 8, 2021
P2, N=270, Active, not recruiting, Sponsor: Biocad
We describe an adverse reaction of leflunomide, LG presenting as episodic bleeding gastric ulcers which resolved after discontinuation of the medication, which was hitherto not described.Figure: Gastric antrum biopsy showing prominent lymphocytes suggestive of lymphocytic gastritis Trial completion date: May 2021 --> Dec 2021
- || teriflunomide / Generic mfg.
Review, Journal: An updated review of teriflunomide's use in multiple sclerosis. (Pubmed Central) - Sep 7, 2021
Data have since become available from active comparator trials with other disease-modifying therapies, treatment-related changes in brain volume (analyzed using structural image evaluation using normalization of atrophy) and real-world evidence including patient-reported outcomes. Initial data on the potential antiviral effects of teriflunomide in patients with MS, including case reports of patients infected with the 2019 novel coronavirus (SARS-CoV-2), are also presented.
- || teriflunomide / Generic mfg.
Switch to Aubagio (Twitter) - Sep 6, 2021
- | Zeposia (ozanimod) / BMS, Mayzent (siponimod) / Novartis
Journal: Identification of Potential Inhibitors against Epstein-Barr Virus Nuclear Antigen 1 (EBNA1): An Insight from Docking and Molecular Dynamic Simulations. (Pubmed Central) - Sep 5, 2021
Computational alanine scanning further supported the significant roles of K477', I481', and K586' in the binding of ligands with EBNA1. Conclusively, the compounds showed promising results to be used against EBNA1.
- || Mavenclad (cladribine) / EMD Serono
Clinical, Journal: What do we currently know about the clinically isolated syndrome suggestive of multiple sclerosis? An update. (Pubmed Central) - Sep 3, 2021
The review presents CIS definition, classification, clinical image, predictive factors, and management. What is more, this is one of very few reviews summarizing the topic in the light of the 2017 McDonald criteria.
- || teriflunomide / Generic mfg.
Clinical, Retrospective data, Journal: COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series. (Pubmed Central) - Aug 26, 2021
What is more, this is one of very few reviews summarizing the topic in the light of the 2017 McDonald criteria. Our report adds to the evidence that COVID-19 is mild in patients receiving teriflunomide therapy and that continuing with teriflunomide therapy during Sars-CoV-2 infection is safe and advisable for MS patients.
- | Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Journal: Ofatumumab - a new drug for the treatment of multiple sclerosis (Pubmed Central) - Aug 21, 2021
This monoclonal antibody provides favorable results for MS by reducing the frequency of exacerbations and the risk of disability progression, significantly more pronounced when compared with teriflunomide. The drug can be used in patients with active relapsing MS and SPMS with exacerbations, with the ineffectiveness of first-line drugs as one of the options for second-line therapy, in patients with highly active MS, especially with a high risk of PML (transfer from natalizumab), as well as if there are difficulties in organizing intravenous courses in day hospitals (produced as outpatient injections).
- | teriflunomide / Generic mfg.
Trial completion date, Trial primary completion date: Mechanistic Studies of Teriflunomide in RRMS (clinicaltrials.gov) - Aug 18, 2021
P=N/A, N=30, Active, not recruiting, Sponsor: University of Michigan
The drug can be used in patients with active relapsing MS and SPMS with exacerbations, with the ineffectiveness of first-line drugs as one of the options for second-line therapy, in patients with highly active MS, especially with a high risk of PML (transfer from natalizumab), as well as if there are difficulties in organizing intravenous courses in day hospitals (produced as outpatient injections). Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Aug 2021 --> Aug 2022
- ||| teriflunomide / Generic mfg.
Trial completion, Enrollment change, Trial completion date: Teriflunomide Observational Effectiveness Study (clinicaltrials.gov) - Aug 18, 2021
P=N/A, N=106, Completed, Sponsor: Centre hospitalier de l'Universit
Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Aug 2021 --> Aug 2022 Enrolling by invitation --> Completed | N=300 --> 106 | Trial completion date: Dec 2019 --> Jun 2021
- |||| Ocrevus (ocrelizumab) / Roche, Biogen
Clinical: #MS_Selfie_Newsletter Case study: Ocrelizumab to Teriflunomide switch. Prof G discusses the case for using ocrelizumab as an induction therapy followed by teriflunomide maintenance therapy. Is this the future? #ClinicSpeak https://t.co/R5sFwokcfc (Twitter) - Aug 16, 2021
- |||||| Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Enrollment open: STHENOS: Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS (clinicaltrials.gov) - Aug 13, 2021
P3, N=236, Recruiting, Sponsor: Novartis Pharmaceuticals
Enrolling by invitation --> Completed | N=300 --> 106 | Trial completion date: Dec 2019 --> Jun 2021 Not yet recruiting --> Recruiting
- || teriflunomide / Generic mfg.
Clinical, Journal, Real-world evidence: Efficacy and Safety of Teriflunomide in Multiple Sclerosis across Age Groups: Analysis from Pooled Pivotal and Real-world Studies. (Pubmed Central) - Aug 12, 2021
Teriflunomide efficacy was demonstrated regardless of age. Safety was generally consistent across age groups.
- || teriflunomide / Generic mfg., leflunomide / Generic mfg.
Clinical, Journal: Precision Medicine with Leflunomide: Consideration of DHODH Haplotype and Plasma Teriflunomide Concentration can Substantially Modify Outcomes in Patients with Rheumatoid Arthritis. (Pubmed Central) - Aug 11, 2021
Safety was generally consistent across age groups. Teriflunomide concentration and carriage of DHODH Haplotype 2 are associated with response to leflunomide in patients with RA, and a total plasma teriflunomide concentration of at least 16 mg/L is needed to maximise the likelihood of response.
- || dimethyl fumarate / Generic mfg.
Clinical, Observational data, Journal: Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study. (Pubmed Central) - Aug 7, 2021
Teriflunomide concentration and carriage of DHODH Haplotype 2 are associated with response to leflunomide in patients with RA, and a total plasma teriflunomide concentration of at least 16 mg/L is needed to maximise the likelihood of response. The results of our study emphasize the importance of education and communication campaigns addressed both to healthcare providers and patients with MS, especially considering that MS patients are currently receiving COVID-19 vaccinations.
- ||| teriflunomide / Generic mfg.
Clinical: I have thought about switching to an immune reconstituting therapy. And have wondered if that would slow progression more than the anti-CD 20 therapy. But I have also thought about switching to some thing with a better safety profile like teriflunomide. (Twitter) - Aug 7, 2021
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] PAEDIATRIC MS (Main Topic A) - Aug 6, 2021 - Abstract #WCN2021WCN_495;
Limited information is available from retrospective studies regarding the safety and efficacy of these drugs in children except for fingolimod and teriflunomide that were studied in a randomized controlled trials in patients 10-17 years of age. Several ongoing trials are investigating the use of dimethyl fumarate and ocrelizumab in pediatric MS and will aid future treatment decisions including short-term safety information.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] COMPARATIVE EFFECTIVENESS OF EARLY INTENSIVE OR ESCALATION TREATMENT STRATEGIES ON LONG TERM DISABILITY TRAJECTORIES IN RELAPSING MULTIPLE SCLEROSIS PATIENTS (Free Communication C) - Aug 6, 2021 - Abstract #WCN2021WCN_228;
EIT group included patients who received, as first DMT natalizumab, fingolimod, alemtuzumab, ocrelizumab, cladribine, mitoxantrone,. ESC group patients received the high efficacy DMT after ≥1 year of injectables DMTs, azathioprine, teriflunomide or dimethylfumarate treatment... Our findings indicate a higher effectiveness of EIT than ESC strategy in slowing disability worsening over time.
- dimethyl fumarate / Generic mfg.
[VIRTUAL] The radiologically isolated syndrome (RIS), is it already MS? (Stream 8 Educational Sessions) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1295;
The recommendation is not to treat off label these subjects as 2 phases 3 studies are ongoing in the USA and Europe with dimethyl fumarate and teriflunomide. A phase IV with ocrelizumab is starting in the USA.
- Utuxin (ublituximab) / TG Therap
[VIRTUAL] Phase 3 results of the ULTIMATE I II global studies: ublituximab versus teriflunomide in relapsing multiple sclerosis (Stream 7 Therapy / Global views) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1206;
A phase IV with ocrelizumab is starting in the USA. The favorable efficacy and safety results of ULTMATE I II demonstrate the potential of UTX, the first 1-hour anti-CD20 infusion, in RMS patients.
- Zinbryta (daclizumab) / Biogen, AbbVie
[VIRTUAL] Blueteq data : EDSS scores in patients on disease modifying therapy at a single centre (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1068;
These results present real world data on the use of EDSS to monitor response to treatment. The Blueteq data is currently limited by a short length of follow up but has potential value over time in tracking mean change in EDSS on each DMT.
- Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Long-term immune-related adverse events after alemtuzumab (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1065;
The autoimmune adverse events are probably related to immune dysregulation due to a differential lymphocyte repopulation following alemtuzumab. Autoimmune adverse events may be frequent, and it would be recommended to monitor its appearance in order to diagnose and treat them.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] Reconstitution of lymphocytes following discontinuation of dimethyl fumarate (DMF) due to lymphopenia in the Swedish post-market surveillance study “Immunomodulation and Multiple Sclerosis Epidemiology 5” (IMSE 5) (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1063;
Data from the Swedish IMSE 5 study suggest that a lymphocyte reconstitution occurs within 13 to 16 weeks following the discontinuation of DMF. However, larger datasets will be needed to verify this finding and also to determine the possible impact of any newly started therapy.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Disease-modifying treatment patterns of patients with multiple sclerosis and newly treated with cladribine tablets or fingolimod: an interim analysis of the CLARION study (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1061;
The most common agents used in the past were interferon beta-1a, DMF, teriflunomide and GA. Teriflunomide was the most common last DMT prior to initiation of CladT or fingolimod.
- glatiramer acetate / Generic mfg., teriflunomide / Generic mfg.
[VIRTUAL] Clinical effectiveness and safety of teriflunomide for patients treated at least 48 months in the Swedish post-market surveillance study “Immunomodulation and Multiple Sclerosis Epidemiology 4” (IMSE 4) (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1050;
TMF demonstrates partly clinical improvements and stability in patients treated ≥ 48 months but with a minor negative outcome of the EDSS scores in this cohort. A longer follow-up period is needed to assess the real-world effectiveness and safety of TMF.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] The influence of disease modifying therapies on immunoglobulin blood levels in patients with multiple sclerosis (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1047;
BCDT further showed a time-dependent decrease of IgG and IgM. Hypogammaglobulinemia may result in a higher susceptibility to infectious diseases.
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Disease activity and patient-reported outcomes in patients with multiple sclerosis switching from first-line platform therapies to dimethyl fumarate (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1037;
P=N/A
Overall, results suggest that DMF is an effective treatment option for patients with RRMS previously treated with injectable therapies or teriflunomide, regardless of the reasons that led to the switch from the previous first-line treatment. Supported by: Biogen
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Real-world patient-reported outcomes in RRMS patients transitioning to alemtuzumab: results from the PRO-ACT study (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1024;
Significant improvements in employment and household productivity were seen after switching, which may reflect a reduction in the burden that MS imposes on patients with employment and household responsibilities. Alemtuzumab safety was consistent with the pivotal studies.
- glatiramer acetate / Generic mfg.
[VIRTUAL] Effect of disease-modifying treatments on cognitive impairment in MS (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_946;
However, the comparison of results is limited by inhomogeneity between groups (more severe patients in the NTZ group) and the performance of tests at different times (older tests for the NTZ and IFN/AG groups). In conclusion, in our study NTZ was a more effective treatment alternative than FTY, TRF and IFN/AG in reducing cognitive impairment.
- teriflunomide / Generic mfg.
[VIRTUAL] Teriflunomide and cognition: a longitudinal study (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_945;
Results suggest that TRF treatment in RRMS has a positive effect in cognitive functioning, and specifically on long term verbal memory, and, to a lesser extent, in inhibition. Neuroimaging correlates are currently being processed and will be presented during the meeting.
- Ponvory (ponesimod) / J&J
[VIRTUAL] Relationships between brain volume and disability, cognition, motor function, and MS-fatigue in RMS: MS-fatigue and ambulation move at their own pace (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_937;
The OPTIMUM study compared ponesimod (20mg) to teriflunomide (14mg) over 108 weeks. There are statistically significant relationships between BV and clinical outcome measures of disability, cognition, motor function, and MS-fatigue; however, ambulation and MS-fatigue were not associated with the PBVC.
- Ponvory (ponesimod) / J&J
[VIRTUAL] Effect of ponesimod compared with teriflunomide on treatment with concomitant corticosteroids for relapse in patients with relapsing forms of multiple sclerosis (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_927;
P3
Reference: Kappos L et al. JAMA Neurol .
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] COVID-19 (inactivated and mRNA) vaccine and humoral response in people with multiple sclerosis: Chilean cohort (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_907;
In our cohort, most of the treatments are likely to produce humoral response to the COVID-19 vaccine, especially alemtuzumab, cladribine and natalizumab, regardless the infusion/administration time. Further study needs to be done that includes more patients with antiCD20 and fingolimod but also it is important that the studies take into consideration the type of vaccine (T cell dependent response), B cell reconstitution and lymphocyte subpopulations for B and T cells.
- Mayzent (siponimod) / Novartis
[VIRTUAL] Safety and tolerability of conversion to siponimod with and without titration in patients with advancing forms of relapsing multiple sclerosis: interim results of the phase 3b EXCHANGE study (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_896;
P3
Immediate conversion from other DMTs to siponimod had an acceptable safety and tolerability profile, with no unexpected findings. There was no evidence of a meaningful reduction in heart rate when initiating siponimod in the overall group or in subgroups stratified by prior DMTs, including subjects transitioning from fingolimod to siponimod without dose titration.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] A retrospective review of COVID spike protein antibody development following COVID-19 vaccination in MS patients on disease modifying drugs (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_889;
This study is limited in retrospective design, small un-balanced groups, and lack of longitudinal data. We cannot exclude the possibility of a more robust delayed humoral response.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] IgG immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within MS PATHS (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_876;
Quantifying post-vaccination IgG response across DMTs is crucial to optimize MS management. Data from ongoing sample collection will be presented at the meeting.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_871;
In addition, we found a superior effect of natalizumab on reducing the rate of disability worsening and improving disability. This study demonstrates the capacity of ATE and ATT MSM to evaluate the effectiveness of multiple MS therapies simultaneously.
- vidofludimus (IMU-838) / Immunic
[VIRTUAL] Safety and tolerability of IMU-838, a next-generation DHODH inhibitor in EMPhASIS: a randomized, placebo-controlled phase 2 trial in relapsing multiple sclerosis (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_869;
P2
In separate phase 2 trials in MS, patients treated with IMU-838 discontinued treatment less frequently and had a lower rate of side-effects typical of DHODH inhibitors than those treated with teriflunomide. The higher selectivity and lower off-target inhibition of protein kinases of IMU-838 may explain the favorable safety and tolerability profile.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Disease-modifying therapy effect on COVID-19 vaccine response in multiple sclerosis patients: data from two New York State Multiple Sclerosis Consortium centers (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_854;
MS patients treated with B-cell depleting medications and S1P modulators have significantly lower seroconversion after COVID-19 vaccination when compared to DMT-naïve patients and other DMT groups. Future studies should determine the risk of severe clinical outcomes in vaccinated patients with no evidence of seroconversion.
- Actemra IV (tocilizumab) / Roche, JW Pharma, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] COVID-19 in patients with multiple sclerosis and neuromyelitis optica spectrum disorder in Colombia (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_838;
No significant differences were observed by sex and treatment type in prognosis and mortality from COVID-19. However, we suggested to carry out robust sample studies to identify the main complicating factors and severity.
- glatiramer acetate / Generic mfg.
[VIRTUAL] Late onset multiple sclerosis Isfahan Iran (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_835;
LOMS patients have high prevalence of comorbidities that differ from adult ms. Furthermore, the family history of MS is statistically significant in our study.